Skip to main content
. 2011 Dec;22(Suppl 8):viii5–viii15. doi: 10.1093/annonc/mdr516

Figure 3.

Figure 3.

Impact of targeted therapy in the Gynecologic Oncology Group (GOG) 170 trials. When the fraction of responses and the fraction of patients with stable disease for 6 months are considered, treatment with bevacizumab has the best outcome (courtesy of Dr Robert Coleman).